Details for Patent: RE47350
Which drugs does patent RE47350 protect, and when does it expire?
Patent RE47350 protects VRAYLAR and is included in one NDA.
Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-seven patent family members in thirty-three countries.
Summary for Patent: RE47350
| Title: | Pharmaceutical formulations containing dopamine receptor ligands | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Richter Gedeon Nyrt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US15/598,971 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE47350 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent RE47350: Cariprazine Formulation Claims, Scope, Expiration and Patent LandscapeUnited States Patent RE47350 protects a low-water-activity solid oral formulation of cariprazine for treating schizophrenia, bipolar disorder, acute mania and depression. The patent does not broadly claim cariprazine as a molecule. Its enforceable scope depends on a combination of formulation composition, dose, dissolution, pH and pharmacokinetic results. The patent is strategically important because the claims can reach a generic product only if the product uses the claimed excipient architecture and produces the specified in vivo profile. The principal commercial product associated with the patent is Vraylar, marketed by AbbVie and containing cariprazine hydrochloride. What drug and formulation does United States Patent RE47350 protect?RE47350 covers pharmaceutical formulations containing trans-cariprazine, formally identified in the claims as:
The active ingredient is commonly known as cariprazine. Commercial cariprazine is generally supplied as the hydrochloride salt. The patent claims a solid oral formulation that must satisfy all of the following conditions:
The claim is therefore a combination claim. A product that contains cariprazine but lacks the specified excipient, dissolution rate, pH or pharmacokinetic profile would not fall within claim 1 based on the claim language supplied. How broad is independent claim 1 of RE47350?Claim 1 is a method-of-treatment claim with formulation limitations. It requires administration to a patient, rather than merely making or selling a tablet. Its breadth comes from four sources:
Its principal limitation is that every recited requirement must be met. The claim does not expressly require a particular tablet weight, manufacturing process, crystalline form, coating, capsule shell or inactive-ingredient concentration. Treatment indication scopeThe indication language covers:
The claim does not appear limited to a particular disease severity, patient age, treatment line or titration schedule. The method must still involve a patient in need of treatment and administration of the claimed formulation. A product approved only for an indication outside the listed conditions would present a different method-of-use analysis. A product labeled for one of the listed conditions would create a more direct infringement risk if its formulation also satisfied the physical and pharmacokinetic limitations. Formulation scopeThe excipient limitation is central. Claim 1 identifies:
The language does not require that these excipients be the only excipients. A formulation could potentially contain additional binders, lubricants, disintegrants, coatings or other inactive ingredients while remaining within the claim, provided the claimed excipient and performance limitations are satisfied. The phrase “low water activity” supplies a functional formulation concept, while the Markush group identifies the expressly claimed excipient alternatives. Water activity is distinct from water content. A tablet with low total moisture is not necessarily within the claim unless the claimed excipient and remaining limitations are also met. What do claims 2 through 10 add?Claims 2 through 10 narrow claim 1 by specifying individual doses, pharmacokinetic thresholds or excipients.
Claims 2 through 7 are dose-specific pharmacokinetic claims. They are not simple dosage claims because each includes a plasma-profile requirement. Claims 8 through 10 isolate the three principal excipient alternatives and may be easier to test analytically than the broader pharmacokinetic limitations. What is the patent expiration date for RE47350?RE47350 is a reissue patent. A reissue does not ordinarily receive a new 20-year patent term. Its term is tied to the underlying original patent and earliest effective nonprovisional priority date. The relevant commercial term is expected to run through December 2029, subject to any applicable patent-term adjustment or extension recorded for the underlying patent. The patent was issued as a reissue on May 7, 2019. Its reissue status does not by itself extend exclusivity beyond the original patent term.
The critical diligence point is that the reissue number should not be treated as a separate 20-year term. Patent-term adjustment, terminal disclaimers and the official USPTO term calculation control the final enforceable date. What is the Orange Book status of cariprazine and Vraylar?Vraylar is FDA-approved cariprazine hydrochloride. The FDA approved Vraylar for schizophrenia and manic or mixed episodes associated with bipolar I disorder in 2015, and later approved it for depressive episodes associated with bipolar I disorder. The FDA label identifies Vraylar as capsules containing cariprazine hydrochloride in multiple strengths. [1] The FDA Orange Book has listed patents associated with Vraylar and cariprazine formulations, including the original patent family associated with RE47350 and later cariprazine patents. Orange Book listing status must be evaluated patent by patent because listed patents may cover different subjects, including:
RE47350 is most relevant to formulation and pharmacokinetic overlap. A generic applicant would need to assess whether its proposed formulation falls within the listed patent claims, not merely whether it contains the same active ingredient. What Paragraph IV challenges could apply to RE47350?A generic applicant could file a Paragraph IV certification asserting that RE47350 is invalid, unenforceable or not infringed. The principal technical positions would likely involve the following issues: Lack of infringementA challenger could design around one or more claim elements by using:
The difficulty is that some limitations are product characteristics, while others are patient pharmacokinetic results. A formulation may produce different Cmax or Tmax values depending on food, patient population, assay method, dose strength and study design. Claim constructionThe parties could dispute the meaning of:
These terms create potential infringement and validity disputes concerning measurement conditions and acceptable analytical variation. Written description and enablementThe patent claims multiple doses, excipient combinations and pharmacokinetic outcomes. A challenger could argue that the specification does not support the full breadth of the claimed ranges or all combinations of dose, excipient and performance limitations. ObviousnessThe core obviousness question would be whether a skilled formulator would have combined cariprazine with one of the specified low-water-activity excipients, selected the claimed pH and dissolution profile, and achieved the claimed plasma exposure. The pharmacokinetic limitations may strengthen patentability if they reflect an unexpected relationship between formulation design and exposure. How strong is the RE47350 patent estate?RE47350 has moderate-to-strong commercial relevance but a narrower infringement perimeter than a basic compound patent.
The patent is stronger against a generic that reproduces the reference product’s formulation and pharmacokinetic behavior. It is weaker against a generic that uses a different excipient system or intentionally changes pH and release characteristics. What manufacturing and formulation barriers does RE47350 create?The patent does not claim a manufacturing process, but its performance limitations can indirectly constrain formulation development. A competing manufacturer would need to control:
Cariprazine is a highly active compound administered at low milligram doses. Small changes in content uniformity, particle properties and dissolution behavior can affect exposure. That makes formulation design and bioequivalence testing material to both regulatory and patent strategy. A design-around must be evaluated experimentally. Simply changing a trade name, capsule color or tablet size would not avoid the patent if all claim limitations remain present. Which companies are challenging Vraylar patents?Publicly reported generic activity concerning Vraylar has involved ANDA applicants and Hatch-Waxman litigation directed at AbbVie’s cariprazine patent portfolio. The relevant analysis should separate:
A Paragraph IV certification does not itself establish invalidity or noninfringement. The commercial result depends on the filed patent claims, court rulings, settlement terms and FDA approval status. What generic launch scenarios exist for cariprazine?The main launch scenarios are:
A generic applicant must clear the entire Orange Book portfolio, not only RE47350. A noninfringing formulation under RE47350 can still face separate substance, method-of-use or formulation patents. How does RE47350 compare with a compound patent?A compound patent generally protects the active molecule against broad use and formulation substitutions. RE47350 is narrower because it requires a defined formulation and clinical-performance profile.
RE47350 is most valuable as part of a layered portfolio. Its commercial effect is greater when combined with other patents covering cariprazine, dosing regimens, formulations or approved uses. Key Takeaways
FAQs About US Patent RE47350 and CariprazineDoes RE47350 cover all cariprazine tablets?No. It covers only solid oral formulations that satisfy the claimed excipient, pH, dissolution and pharmacokinetic requirements and are used for a listed condition. Can a generic use cariprazine without infringing RE47350?Yes, potentially. A generic may avoid infringement by using a different excipient system, pH, dissolution profile or formulation that does not produce the claimed pharmacokinetic results. Other cariprazine patents may still block launch. Does RE47350 cover cariprazine hydrochloride?The claims cover cariprazine and pharmaceutically acceptable salts. Cariprazine hydrochloride is within the salt language if the remaining limitations are satisfied. Is a Paragraph IV challenge to RE47350 automatically a generic launch approval?No. FDA approval, patent litigation, other Orange Book-listed patents and any settlement agreement independently affect launch timing. Why are the Cmax and Tmax limits important?They convert the patent from a simple ingredient-and-excipient claim into a performance-based claim. A generic formulation can avoid the claim only if its measured clinical profile falls outside the relevant thresholds or another claim element is absent. References
More… ↓ |
Drugs Protected by US Patent RE47350
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-005 | Dec 18, 2025 | RX | Yes | No | RE47350*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-006 | Dec 18, 2025 | RX | Yes | No | RE47350*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-001 | Sep 17, 2015 | RX | Yes | Yes | RE47350*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE47350
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2975 | ⤷ Start Trial | |||
| Australia | 2009270823 | ⤷ Start Trial | |||
| Brazil | PI0916241 | ⤷ Start Trial | |||
| Canada | 2730287 | ⤷ Start Trial | |||
| Chile | 2011000091 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
